Impact of early minimal residual disease assessment on the outcomes of patients with systemic light chain amyloidosis.

ABSTRACT:

Background

Systemic light chain (AL) amyloidosis is associated with a high mortality rate, particularly in the first year after diagnosis. Minimal residual disease (MRD) assessment plays a key role in the prognosis of AL amyloidosis but is typically performed later in the treatment process, thereby limiting its ability to guide early interventions.

Materials and methods

This retrospective study included 53 newly diagnosed AL amyloidosis patients who underwent MRD assessment via flow cytometry after two chemotherapy cycles. The aim of this study was to assess the effect of early MRD negativity on organ response kinetics and prognosis.

Results

After two chemotherapy cycles, 22.6% (12/53) of patients achieved early MRD negativity. Daratumumab-treated patients had

SUBMITTER: Li X 

PROVIDER: S-EPMC12584825 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature